Combination chemotherapy in murine neuroblastoma.
The C1300 murine neuroblastoma system has been studied to determine its relevance as a chemotherapy model to the human disease. Studies using combination therapy revealed that BCNU/cyclophosphamide combination therapy increased the median lifespan 300% in A/J mice bearing the C1300 tumor. Cyclophosphamide/imidazole carboxamide and adriamycin/imidazole carboxamide combinations were less active, increasing median lifespans 189% and 144%, respectively. Vincristine/bleomycin were inactive even when the schedule was adjusted to coincide with the time of maximum mitoses following vincristine injections. These results suggest the BCNU/cyclophosphamide combination chemotherapy may be effective in human disease.
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001761:Bleomycin / Q000627:therapeutic use / Q000633:toxicity; D002330:Carmustine / Q000627:therapeutic use / Q000633:toxicity; D003520:Cyclophosphamide / Q000627:therapeutic use / Q000633:toxicity; D004195:Disease Models, Animal; D004317:Doxorubicin / Q000627:therapeutic use / Q000633:toxicity; D004359:Drug Therapy, Combination; D007093:Imidazoles / Q000627:therapeutic use / Q000633:toxicity; D008297:Male; D051379:Mice; D008805:Mice, Inbred A; D008938:Mitosis / Q000187:drug effects; D009374:Neoplasms, Experimental / Q000188:drug therapy / Q000401:mortality; D009447:Neuroblastoma / Q000188:drug therapy* / Q000401:mortality; D014750:Vincristine / Q000627:therapeutic use / Q000633:toxicity
D000970:Antineoplastic Agents; D007093:Imidazoles; D001761:Bleomycin; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D002330:Carmustine